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Abstract
Ionized calcium was involved in various cellular signal pathways,and regulates many cellular processes, including those
relevant to tumorigenesis. We hypothesis that imbalance of calcium homeostasis is correlated with development of lung
carcinomas. We collected the clinical data of 1084 patients with non small cell lung cancer (NSCLC) treated in Shandong
Provincial Hospital, Shandong University. Logistic regression was used to determine the association between calcium levels
and clinical characteristics, and COX regression and Kaplan-Meier model were applied to analyze risk factors on overall
survival. Blood electrolytes were tested before treatment; and nearly 16% patients with NSCLC were complained with
decreased blood calcium, which is more frequent than that in other electrolytes. Further, Multivariate logistic regression
analysis disclosed that there were significant correlation between blood calcium decrease and moderate and poor
differentiation (P=0.012, OR=1.926 (1.203–4.219)), squamous cell carcinoma (P=0.024, OR=1.968(1.094–3.540)), and bone
metastasis (P=0.032, OR=0.396(0.235–0.669)). In multivariate COX regression analysis, advanced lymph node stage and
decreased blood calcium were significantly and independent, unfavorable prognostic factors (P,0.001). Finally, the Kaplan-
Meier Survival curve revealed that blood calcium decrease was associated with shorter survival (Log-rank;
x
2=26.172,P,0.001). Our finding indicates that lower blood calcium levels are associated with a higher risk of unfavorable
prognosis and bone metastasis of NSCLC.
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Introduction
Lung cancer is the most common malignancy all over the world
and the leading cause of death in men [1]. A series of studies have
investigated the relationship between calcium and lung cancer,
especially cancer related hypercalcaemia. However, few studies
focus on association between the hypocalcaemia and lung cancer.
Calcium signal is a ubiquitous cellular signaling, which regulates
cell death and proliferation by activating or inhibiting cellular
signal pathways and calcium-regulated proteins [2]. Extracellular
free calcium is about ,1.2 mM [3], and free calcium intercellular
is 100 nM,1 mM. The aspects and degree in free calcium is
associated with many pathways [4–7]. Thus, calcium regulates
various cellular processes, including those relevant to tumorigen-
esis, such as cell motility, angiogenesis, gene transcription,
apoptosis and proliferation. The intracellular calcium signaling is
implicated in invasion [8,9], and extracellular calcium is associated
with bone metastasis [10]. Calcium plays a key role in
angiogenesis, such as VEGF can increase intracellular calcium
by mobilizing calcium release from internal stores [11]; calcium
is a modulator of poly (ADP-ribose) polymerase-1(PARP1)
activity [12]. Calcium signaling is implicated in the differentiation
process either through the extracellular calcium sensing receptor
and/or alteration in intracellular calcium, which results in cancer
cells to be dedifferentiated in the tumorigenic process [13].
Calcium is also involved in regulating cell cycle and apoptosis
[14,4, and 5]. Reduction in the calcium content of the lumen of
the endoplasmic reticulum is associated with resistance to
apoptosis [5,15].
Currently, most studies about calcium focus on the relationship
between calcium intake and the risk of aggressive or clinically
relevant cancers [16–21]. Primary lung cancer complicated by
hypercalcaemia was 26%. Hypercalcaemia may be due to the
increased activity of osteoclasts causes bone calcium into the
extracellular fluid caused by bone metastases; or caused by tumor
secreted PTHrP. However, in our clinical practice, there were
nearly 16% NSCLC patients with hypocalcaemia. The critical role
of calcium in NSCLC progression remains uncertain. We
hypothesis that lung carcinoma could break blood calcium
homeostasis, whereas the imbalance of calcium will also have
effects on the tumorigenesis and development of lung cancer.
To confirm the hypothesis, we collected the clinical data of lung
cancer patients; tested the blood calcium levels; and followed up
the patients. It is hopefully to find out the relationship between
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34264blood calcium decrease and clinical staging, bone metastasis,
differentiation and prognosis of lung carcinoma.
Results
Among the eligible 1084 patients, 175 cases were accompanied
with blood calcium,2.2 mM, 11 cases magnesium decreased, 8
cases potassium decreased, 9 cases sodium decreased and 4 cases
chlorine decreased. Data was shown in Table 1. The patients with
blood electrolytes increased were not included, because the cases
were too less to do statistic analysis. We found blood calcium
decreased was more frequent than that in other electrolytes
(P,0.05) (Table 1).
Of 1084 accrued cases, 175 cases were followed with blood
calcium,2.2 mM, 901 patients blood 2.2#calcium#2.6 mM, and
8 cases calcium.2.6 mM. Patients’ characteristics, grouped by
calcium levels, were shown in Table 2. Among the 175 patients,
Table 1. The changes of Blood electrolytes in 1084 cases with
NSCLC.
Blood
electrolytes Calcium Magnesium Potassium Sodium Chlorine
Decreased 175 11 8 9 4
Normal 901 1064 1071 1068 1074
Increased
1 89 5 7 6
P ,0.05
#
NSCLC: non small cell lung cancer;
1These cases is not included, because it is too less and not enough for statistic
analyses;
#the incidence of calcium decrease compare with others blood electrolytes,
including magnesium, potassium, sodium and chlorine.
doi:10.1371/journal.pone.0034264.t001
Table 2. Relations of clinical and pathological characteristics and Blood Calcium levels in NSCLC patients.
Characteristics No. of patients
Calcium,2.2 2.2, =Calcium. =2.6 Calcium.2.6
1 Chi-square P value
Sex
Male 127 643 6 0.103 0.78
Female 48 258 2
Age
,60 63 410 3 5.374 0.024
. =60 112 491 5
Smoking Index
Never 53 351 2 5.539
a 0.019
a
,400 14 82 1
. =400 108 467 5
Tumor differentiation
Well 11 231 1 32.308
b 0.000
b
Moderately 110 472 5
Poorly 55 198 2
Histology
Adenomas 63 445 5 11.871
c 0.003
c
Squamous 101 394 3
Others 11 62 0
LN metastasis
& 108 464 5
Negative 43 246 3 6.109 0.013
Positive 65 218 2
Bone metastasis
h 96 432 0
Negative 69 374 11.500 0.001
Positive 27 58
Stage
I 31 183 0 0.62 0.431
II–IV 144 718 8
1These variables is not included, because it is too less and not enough for statistics analysis;
&This variable just included the resected NSCLC cases;
hThese cases came from the follow-up of resected NSCLC patients who were not detected bone metastases at primary care;
LN: Lymph node;
aCompare of never smokers to smoking index. =400;
bCompare of well differentiation to moderately and poorly differentiation;
cCompare of adenomas with squamous lung carcinomas, because others is too less and have special features.
doi:10.1371/journal.pone.0034264.t002
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blood calcium levels and clinical and pathologic characteristics.
There were no significant differences observed in gender
(x
2=0.103, P=0.78) and staging (x
2=0.62, P=0.431). However,
calcium decrease was significantly more prevalent in patients from
age$60 than age,60 (P=0.024); from smokers than non-smokers
(P=0.019); in moderately and poorly differentiated tumors than in
well differentiated tumors (P,0.001); in squamous cell carcinoma
than adenocarcinoma (P=0.003); and in pN0 tumors than in
pN$1 tumors (P=0.013). x
2 tests showed that decreased baseline
of calcium was a predictor for bone metastasis (x
2=11.5,
P,0.001) (Table 2).
Multivariate logistic regression analysis for the association of
calcium levels with various charactristics disclosed that there were
significant correlation between calcium decrease and moderate
and poor differentiation (P=0.012, OR=1.926 (1.203–4.219)),
squamous cell carcinoma (P=0.024, OR=1.968(1.094–3.540)),
and bone metastasis (P=0.032, OR=0.396(0.235–0.669))
(Table 3).
Further, chi-square tests were applied to analyze correlation
between univariate analyses of clinical and pathologic character-
istics and overall survival in 572 patients who were eligible for
survival analysis (see the material and methods). As shown in
Table 4, gender, tumor differentiation, lymph node metastasis, p-
staging and blood calcium were significantly correlated with
prognosis (P,0.05) (Table 4). In multivariate Cox Regression
analysis, only advanced lymph node stage and decreased blood
calcium were significantly and independently unfavorable prog-
nostic factors (P,0.001) (Table 5).
Finally, we analyzed the effects of blood calcium decrease on
survival using the Kaplan-Meier Survival Model in 572 patients
who underwent radical resection, including 108 cases with blood
calcium,2.2 mM and 464 cases with 2.2#calcium#2.6 mM
(Fig. 1). Log-rank comparisons revealed that blood calcium
decrease(,2.2 mM) was associated with shorter survival (Log-rank;
x
2=26.172, P,0.001).
Discussion
In current study, the integrated and advanced bio-bank was
used to examine association between blood electrolytes and
NSCLC. We found decreased blood calcium correlated with poor
prognosis, poor tumor differentiation, and squamous cell carcino-
ma. We also found that decreased blood calcium at initial care
may be a predictor for bone metastasis. In previous studies, blood
calcium levels correlated with aggressive cancers have generated
mixed results [16–19,22–24]. Many studies have shown that a
high intake of calcium may increase the risk of prostate cancer,
and the possible reason is high dietary intake of calcium would
lead to lower vitamin D which is an established risk factor for
prostate cancer [25]. However, there were also studies found no
strong association between dietary calcium intake and risk of
prostate cancer [26]. The role of calcium in tumorigenesis is
unclear. Our study may be the first focus on the correlation
between decreased blood calcium and clinical characteristics and
prognosis of NSCLC.
As mentioned above, we believe the ionized calcium plays an
important role in lung cancer development. Blood electrolytes
were tested before treatments; and we found nearly 16% patients
with NSCLC were complained with decreased blood calcium, Table 3. Multivariate Logistic Regression Analysis for the
correlation between calcium levels and clinical characteristics.
Variable
q
Adjusted OR
(95%CI) P Value
Age
,60 0.720(0.433–1.199) 0.207
. =60
Smoking Index
Never 1.246(0.657–2.363) 0.50
. =400
Tumor differentiation
Well 1.926(1.203–4.219) 0.012
Moderately and poorly
Histology
Adenomas 1.968(1.094–3.540) 0.024
Squamous
LN metastasis
&
Negative 0.714(0.427–1.195) 0.20
Positive
Bone metastasis
h
Negative 0.396(0.235–0.669) 0.032
Positive
qThese variables were significantly correlated with Blood Calcium, which were
shown in Table 2;
&This variable just included the resected NSCLC cases;
hThese cases came from the follow-up of resected NSCLC patients who were
not detected bone metastases at primary care;
OR: Odds Ratio; CI: confidence Intervial; LN: Lymph node.
doi:10.1371/journal.pone.0034264.t003
Table 4. Univariate analysis of clinical characteristics’ affect
on 3 years survival.
Characteristics Chi-square P value
Sex
Female vs Male 6.783 0.009
Age
,60 vs . =60 1.374 0.088
Smoking Index
Never vs . =400 0.935 0.241
Tumor differentiation
Well vs Moderately and Poorly 23.803 ,0.01
Histology
Adenomas vs Squamous 0.781 0.356
LN metastasis
&
Negative vs Positive 16.109 0.003
Bone metastasis
h
Negative vs Positive 1.047 0.158
Stage
I vs II–IV 10.744 0.006
Calcium
,2.2 vs $2.2, #2.6 8.462 0.027
&This variable just included the resected NSCLC cases;
hThese cases came from the follow-up of resected NSCLC patients who were
not detected bone metastases at primary care;
LN: Lymph node.
doi:10.1371/journal.pone.0034264.t004
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reasonable to speculate that tumor differentiation and clinical
staging might modify the relationship between blood calcium
levels and NSCLC risk.
It has been shown that calcium level played a role in the
development and progression of breast and prostate cancers
[27,28]. A high level of serum calcium is associated with
aggressive, poorly differentiated lesions or fatal prostate cancer,
which means calcium homeostasis is important to keep body in
normal [29,30]. The broken of calcium homeostasis will promote
lung cancer development, which is very harmful to NSCLC
patients. Given the broad range of biological functions dependent
on calcium, it is highly plausible that calcium deficiency may affect
multiple pathways in tumorigenesis. For instance, a recent study
found extracellular calcium may function to regulate the
differentiation of colonic epithelial cells and may contribute to
abnormal differentiation and malignant progression [31]. Inter-
cellular calcium strongly affected by extracellular calcium
regulates prostate cancer cell growth and results in a greater
proportion of unaggressive tumors [32], which is consistent to our
finding.
To confirm the association between decreased blood calcium
and NSCLC bone metastasis, we tested the blood calcium among
the patients without bone metastasis; and followed up them at least
36 months for the alives. We found decreased calcium is strongly
associated with bone metastasis compare with calcium in normal.
The possible reasons are that hypocalcaemia stimulates secretion
of parathyroid hormone to increase blood calcium and enhance
osteolytic cells to break bone, resulting in osteoporosis, which
provides opportunity for cancer cells invasive the bones. This view
need more evidences to confirm, and we will do further studies to
clear the mechanisms.
Our study at least to some degree provides one possible
evidences for some inconsistency in the previous studies. Our
finding indicates that lower blood calcium levels are associated
with a higher risk of unfavorable prognosis and bone metastasis of
NSCLC. These findings, if confirmed, may provide a new way for
the personalized adjuvant care and novel predictor for bone
metastasis of NSCLC.
Materials and Methods
Patients
The study was approved by the Ethical Committee of Shandong
Provincial Hospital affiliated to Shandong University. All patients’
records were from the Bio-Bank of Shandong Provincial Hospital.
A retrospective cohort design was applied to assess and identify all
pathologically confirmed, newly diagnosed cases of primary non
small cell lung cancer during January 2006 and June 2008. All
patients received a primary care, and most patients obtained their
longitudinal care in Shandong Provincial Hospital. Criteria for
eligibility included Karnofsky performance score $70, weight loss
#5% in the prior 3 months, 18#age#75, blood electrolytes assay
at first visit and not other chronic diseases such as diabetes mellitus
and hypertension. There were 1267 patients newly diagnosed as
lung cancer during January 2006 and June 2008, and 1084 cases
were eligible,including 572 resected and 512 non-resected
NSCLC. The level of blood electrolytes was tested before primary
treatment. Overall survival was analyzed in 572 patients: a.
survived for .3 months after surgery, b. followed up at least 3
years after surgery for the alives, c. did not die of any other reasons
excluding lung cancer. Written informed consent was obtained
from all participating subjects.
To ensure reliable and consistent data collection, two
independent trained physicians who were supervised by the study
team were assigned to review the relevant database of each case.
Otherwise all conflicts were discussed to obtain agreement. After
the review, we excluded patients who died in one month from
primary care; death reasons were not malignancy and whose
pathologic diagnoses were not done in Shandong Provincial
Hospital.
Statistical Analysis
The relations between blood calcium levels and clinical and
pathological characteristics were analyzed by chi-square tests or
Fisher exact tests. Multivariate logistic regression analysis was
applied to estimate the factors on blood calcium. Chi-square tests
were used to evaluate correlations between single variable and
overall survival. The correlations between multiple variables and
Table 5. Multivariate analysis of clinical characteristics affect
on 3-year survival using COX regression model.
Variables
g HR(95%CI) P value
Sex
Female vs Male 1.034(.0722–1.481) 0.856
Tumor differentiation
Well vs Moderately and Poorly 1.348(0.547–3.324) 0.516
LN metastasis
Negative vs Positive 2.237(1.469–3.406) 0.000
Stage
I vs II–IV 0.742(0.511–1.077) 0.117
Calcium
,2.2 vs . =2.6 2.697(1.590–4.574) 0.000
gThese variables were selected from the variables that have effects on 3-year
survival using univariate analysis;
HR: Hazard Ratio; CI: Confidence Interval; LN: Lymph node.
doi:10.1371/journal.pone.0034264.t005
Figure 1. The Kaplan-Meier survival curve of NSCLC patients
who underwent radical resection (n=572). It is analyzed using
Kaplan-Meier survival model, including 108 cases with blood calcium
,2.2, and 464 cases with 2.2,=calcium,=2.6. Log-rank comparisons
revealed that blood calcium decrease(,2.2 mM) was associated with
shorter survival (Log-rank; x
2=26.172, P,0.001).
doi:10.1371/journal.pone.0034264.g001
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model. Variables entered into the multivariate COX regression
models were owed from the variables that were statistically
significant at the 0.1 level in univariate analysis. The Kaplan-
Meier survival curves were applied to assess the effects of blood
calcium on 3-year Survival, and the log-rank test was used to
evaluate the differences in survival distributions. P,0.05 was set as
statistical significance. All the statistical analyses were completed
by SPSS software (version 17.0).
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